Evidence map›Paper›PMID 36590296›Full record

ArticleFrontiers in neuroscience2022

Dulce-María Arzate, Concepción Valencia, Marco-Antonio Dimas, Edwards Antonio-Cabrera, Emilio Domínguez-Salazar, Gilda Guerrero-Flores, Mariana Gutiérrez-Mariscal, Luis Covarrubias

Open access · goldAbstract read
In one paragraph

Article in Frontiers in neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Dulce-María ArzateInstituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, Mexico.
Concepción ValenciaInstituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, Mexico.
Marco-Antonio DimasInstituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, Mexico.
Edwards Antonio-CabreraDepartamento de Biología de la Reproducción, Universidad Autónoma Metropolitana Unidad Iztapalapa, Ciudad de México, Mexico.
Emilio Domínguez-SalazarDepartamento de Biología de la Reproducción, Universidad Autónoma Metropolitana Unidad Iztapalapa, Ciudad de México, Mexico.
Gilda Guerrero-FloresInstituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, Mexico.
Mariana Gutiérrez-MariscalInstituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, Mexico.
Luis CovarrubiasInstituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, Mexico.
Universidad Nacional Autónoma de México · MXUniversidad Autónoma Metropolitana · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The Notch pathway is fundamental for the generation of neurons during development. We previously reported that adult mice heterozygous for the null allele of the gene encoding the Delta-like ligand 1 for Notch ( Methods: Brains of Results: Brain weight and size of Discussion: Our observations suggest that Dll1 haploinsufficiency limits Notch signaling during brain development which, on one hand, leads to reduced brain cell density and causes microcephaly and hydrocephalus phenotypes and, on the other, alters the myelination process after birth. The severity of these defects could reach levels that affect normal brain function. Therefore, Dll1 haploinsufficiency is a risk factor that predisposes the brain to develop abnormalities with functional consequences.

Indexed as

hydrocephalusmicrocephalymyelinationneuronal densitynotch signaling

Identifiers

PMID36590296
PMCPMC9794864
OpenAlexW4311358613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.